OptimizeRx to Acquire PatientPoint Group Holdings
Ticker: OPRX · Form: 8-K · Filed: Apr 18, 2024 · CIK: 1448431
| Field | Detail |
|---|---|
| Company | Optimizerx CORP (OPRX) |
| Form Type | 8-K |
| Filed Date | Apr 18, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, merger, digital-health
TL;DR
OptimizeRx buying PatientPoint to boost digital health game.
AI Summary
OptimizeRx Corp announced on April 16, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of PatientPoint Group Holdings, LLC. The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions. This acquisition aims to expand OptimizeRx's reach within the digital health ecosystem.
Why It Matters
This acquisition could significantly expand OptimizeRx's presence in the digital health market, potentially leading to increased market share and revenue growth.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overpayment, and failure to achieve expected synergies.
Key Players & Entities
- OptimizeRx Corp (company) — Acquiring company
- PatientPoint Group Holdings, LLC (company) — Target company
- April 16, 2024 (date) — Date of definitive agreement
- second quarter of 2024 (date) — Expected closing period
FAQ
What is the primary strategic rationale behind OptimizeRx's acquisition of PatientPoint?
The acquisition is intended to expand OptimizeRx's reach within the digital health ecosystem.
When is the acquisition of PatientPoint expected to be completed?
The transaction is expected to close in the second quarter of 2024.
Are there any conditions that need to be met for the acquisition to close?
Yes, the transaction is subject to customary closing conditions.
What is the name of the company OptimizeRx is acquiring?
OptimizeRx is acquiring PatientPoint Group Holdings, LLC.
On what date was the definitive agreement for the acquisition announced?
The definitive agreement was announced on April 16, 2024.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-04-18 16:30:14
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 Par Value OPRX The Nasdaq Capital M
Filing Documents
- ea0204128-8k_optimizerx.htm (8-K) — 25KB
- ea020412801ex99-1_optimizerx.htm (EX-99.1) — 133KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-034128.txt ( ) — 348KB
- oprx-20240416.xsd (EX-101.SCH) — 3KB
- oprx-20240416_lab.xml (EX-101.LAB) — 33KB
- oprx-20240416_pre.xml (EX-101.PRE) — 22KB
- ea0204128-8k_optimizerx_htm.xml (XML) — 4KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On April 16, 2024, OptimizeRx Corporation issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023, providing Key Performance Indicators and reiterating its initial 2024 guidance. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 and Exhibit 99.1 attached hereto are furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release, dated April 16, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OPTIMIZERX CORPORATION Date: April 18, 2024 By: /s/ Edward Stelmakh Name: Edward Stelmakh Title: Chief Financial Officer 2